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Hepatitis E virus (HEV) infection has been identiﬁed as a cause of
graft hepatitis in liver transplant recipients. The true frequency
and clinical importance of HEV infections after liver transplanta-
tions is a matter of debate. It is proposed that consumption of
HEV-contaminated undercooked meat is a main source for HEV
infections in developed countries – which might also account
for some hepatitis E cases after organ transplantation. However,
HEV is also transmitted by transfusion of blood products, likely
representing a previously underestimated risk particularly for
patients in the transplant setting. HEV infection can take chronic
courses in immunocompromised individuals, associated in some
cases with rapid progression to cirrhosis within 1–2 years of
infection. Diagnosis in transplanted patients is based on HEV
RNA testing as antibody assays are not sensitive enough. Selec-
tion of immunosuppressive drugs is important as different com-
pounds may inﬂuence viral replication and the course of liver
disease. Ribavirin has antiviral activity against HEV and should
be administered for at least three months in chronically infected
individuals; however, treatment failure may occur. HEV infec-
tions have also been linked to a variety of extrahepatic manifes-
tations both during and after resolution of infection.
In this review we summarize the emerging data on hepatitis E
with a particular focus on the importance of HEV infections for
liver transplant recipients.
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Hepatitis E is caused by infection with the hepatitis E virus (HEV).
An infectious agent, leading to acute hepatitis that differed from
HAV and HBV, was already suspected in the 1970s. In 1983,
Balayan and colleagues showed that oral administration of
pooled stool extracts from patients with non-A/non-B hepatitis
led to acute hepatitis in a human volunteer in whom virus-like
particles were identiﬁed in stool samples [1]. Hepatitis E was ini-
tially recognized only as an acute self-limited liver disease, which
very rarely progressed to acute liver failure. Severe courses were
most often observed in pregnant women [2,3] and individuals
with chronic liver diseases [4–7]. HEV infections were reported
mainly from endemic countries such as the Indian subcontinent,
South-East Asia and Sub-Saharan Africa. During the last 3 decades
large scale outbreaks of hepatitis E were reported [8–11], even
continuing until recently when many hepatitis E cases were
reported in refugee camps in South Sudan [12].
For more than 25 years HEV infection was not considered a
major clinical problem in developed countries including Europe
and the United States. The description of chronic courses of
HEV infections in solid organ transplant recipients in France in
2008 [13] increased the awareness for a potentially largely
underestimated disease. Since then, persistent HEV infections
were described in different cohorts of immunocompromised
patients [9,14] but also beyond organ transplantation [15–19].
Subsequently, mechanisms leading to persistent infection were
explored in more detail and antiviral therapies were tested in
large case series. Importantly, HEV infections seem to take very
rapid and aggressive courses in many patients receiving immuno-
suppressive medications and HEV has been linked with end-stage
liver disease and even liver-associated mortality. HEV infections
seem to be much more common in Europe than previously
thought. Between 10% and 50% of the populations were anti-
HEV-positive in various epidemiological studies [20–22]. Thus,
millions of – usually clinically silent – infections occur each year
in Europe but only a small proportion of infected individuals
develop clinical symptoms. HEV infection should also be consid-
ered in the differential diagnosis of drug-induced liver disease
[23,24], which has also a major importance in the management
of liver transplant recipients, receiving various medication before
and after transplantation. Of note, HEV has also been linked to
extrahepatic manifestations and thus, the clinical implications14 vol. 61 j 1418–1429
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of hepatitis E virus infections are likely to be much broader than
previously estimated [25–28].
Key Points
• Hepatitis E virus infection can take chronic courses in 
immunocompromised individuals. There is limited data 
suggesting that chronic courses may be more frequent 
after liver transplantation
• Chronic hepatitis E is often associated with rapid 
progression to liver cirrhosis
• HEV genotype 3 infection can be a zoonosis and HEV 
is believed to be transmitted mainly by ingestion of raw 
uncooked meat. Other sources of transmission are food 
hygiene and transfusion of HEV positive blood products
• Different immunosuppressive drugs may have 
distinct effects on HEV replication (either inhibitory 
or stimulatory) and should therefore be selected 
accordingly
• Ribavirin can be used to treat HEV infection and should 
be given for at least 3 months. Treatment failures may 
occur and require further investigationHEV virology
HEV is a small (27–34 mm) non-enveloped virus which belongs
to the family of Hepeviridae. It is encoded by a single-stranded
RNA (7.2 kb) which consists of three open-reading frames
(ORF1–3) [29]. The non-structural proteins are encoded by
ORF1 and their translation leads to the synthesis of proteins
which are primarily essential for viral replication. In particular,
it consists of a methyltransferase, a protease, a macrodomain, a
helicase and an RNA-dependent RNA-polymerase [30]. Of note,
a hypervariable region (HVR) is localized between the protease
and the macrodomain. ORF 2 and ORF 3 on the other hand encode
for the structural proteins. The capsid, which is essential for viral
attachment and entry into liver cells, is the translational product
of ORF2 [31,32]. ORF 3 partly overlaps with ORF2 and leads to the
production of a small phosphoprotein, which is involved in the
assembly and release of the virus and has been shown to interact
with cellular host factors [33].
Similar to other RNA-viruses different genotypes of HEV exist
due to a lack of proof-reading activity of the RNA-dependent
RNA-polymerase. So far, 5 different HEV genotypes have been
identiﬁed, which differ in their nucleotide sequences by 19%.
Intra-genotypic differentiation into sub-genotypes is made upon
a variation of approximately 12% [34]. These distinct genotypes
differ markedly in their distribution, clinical presentation and
species-speciﬁcity.
It is believed, that only genotypes 1, 2, 3 and 4 are able to
cause apparent disease in humans, while genotype 5 has been
identiﬁed only in birds thus far [14]. While genotype 1 and 2
solely infect humans, genotype 3 and 4 are zoonotic pathogens
with likely major reservoirs in pigs [35–37], wild boars and deer
[38–40]. Some data suggest that genotype 1 may also be able to
infect pigs [41], which however needs to be conﬁrmed byJournal of Hepatology 2014additional studies. The worldwide distribution of the different
genotypes varies markedly. Genotype 1 and 2 infections have
been reported mainly in Asia, India and North-Africa. Genotype
2 HEV has been also identiﬁed in Mexico [14,42]. Genotype 3 is
present in Western countries as well as in Asia and North Amer-
ica while genotype 4 has been detected in Asian- as well as in
European countries [14]. However, genotype 4 might also play
a minor role in Europe as supported by recent data, demonstrat-
ing evidence for a genotype 4 infection in France [43].
Additionally, several related viral strains have been identiﬁed
in a variety of species like bats [44], chicken [45], ferrets [46],
rabbits [47], rats [48] and trout [49]. However, it is believed that
these viruses are not able to infect humans.Routes of HEV transmission
Distinct HEV genotypes differ in their route of transmission. Con-
taminated water is the main source for genotypes 1 and 2 infec-
tions. Large hepatitis E outbreaks have been described in various
African and Asian countries including India, China, Somalia, South
Sudan or Uganda [8–10,14]. In contrast, HEV genotype 3 and 4
usually cause sporadic infections, most likely due to consumption
of contaminated food. HEV-RNA has been detected in a variety of
food products in particular porcine livers and pig sausages in
France, the US, the Netherlands and Germany [35,36,50,51].
Consumption of such food increases the likelihood for the devel-
opment of HEV-infection [43,51–54]. In line with this, people
who have close contact to swine and deer – farmers, slaughter-
house-workers, veterinarians – display a signiﬁcant higher prev-
alence of HEV-infections compared to the general population
[55,56]. Recent publications have delineated that HEV-RNA is
even more widely distributed than previously thought, and has
been found in various food-products like shellﬁsh [57], mussels
[58,59], green vegetables [60] as well as ﬁeld-grown strawberries
[61] (Fig. 1).HEV transmission by blood products and organ
transplantation
Organ transplant recipients frequently receive blood products,
either prior to transplantation, during, or after transplantation.
In most Western countries, blood products are tested for
HCV-RNA and HIV-RNA by mini-pool testing and often even for
HBV-DNA. However, blood products are not tested for HEV-
RNA, even if transfused to individuals at risk. Several previous
case reports suggested that HEV transmission by blood products
is possible [14,62], which can obviously also occur after liver
transplantation as demonstrated recently by Coilly et al. [63].
Clinically healthy European blood donors may carry HEV RNA
as reported during the last 2 years for Scotland [64], Sweden
[65], England [66], Germany [67,68] and the Netherlands
[69] – even though the absolute HEV RNA prevalence is low
(0.01–0.04%). Still, the risk for HEV transmission may become
substantial if blood products are pooled. In this case, the risk
for HEV transmission seems to be substantial as up to 10% of
pooled plasma products tested HEV RNA positive in Europe
[65]. Indeed, plasma products seem to be a speciﬁc cause for
HEV infections [62,70]. However, screening of blood products
for HEV has not been standardized in any country until now.
Currently, there is an ongoing debate concerning this issue.vol. 61 j 1418–1429 1419
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Fig. 1. Transmission and disease-progression in transplanted individuals. The possible mode of HEV-transmissions is illustrated. Additionally, known factors which
inﬂuence the clinical course are depicted. Treatment options are highlighted in blue.
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the potential signiﬁcance of testing blood products for HEV [71].
This has been further supported by the work of Hewitt et al.,
which was published in Lancet very recently. Here, the authors
retrospectively screened blood donations that were collected in
southeast England between October 2012 and September 2013
for HEV-RNA. Out of 225,000 blood donations, 79 patients were
viraemic with genotype 3 HEV. The authors could follow-up 43
recipients of HEV-positive blood components and 42% of these
individuals displayed evidence for infection with HEV thereafter.
Short-term morbidity was rather low as only one of these indi-
viduals developed clinical signiﬁcant symptoms. However, 10
patients, including organ transplant recipients who were receiv-
ing immunosuppressive medications, displayed prolonged viral
infection [72].
HEV is not only transmitted by blood products but also by the
transplanted organ itself (Fig. 1). Of interest, in one case report a
HEV-RNA positive liver has been transplanted to a HEV-negative
recipient. The development of a chronic HEV-infection rapidly led
to re-cirrhosis of the graft [73]. It is important to note that organ
transplants are not tested for HEV RNA. Stem cells may represent
another risk for HEV infection. Recently, a stem cell donor has1420 Journal of Hepatology 2014been identiﬁed who was clinically healthy at the time of evalua-
tion but who suffered from acute hepatitis E at the time of leu-
copheresis [74].Seroprevalence
The evaluation of the prevalence of HEV, as determined by the
detection of anti-HEV IgG, is hampered by marked differences
in the sensitivities and speciﬁcities of the antibody assays
[75,76]. For example, a comparison of different commercial
assays revealed a variation of anti-HEV IgG-positive individuals
between 3.6% and 16.2% in blood donors from the UK [21]. The
sensitivity thereby ranged from 56 to 98%. In the US an anti-
HEV prevalence of around 25% has been proposed [77]. Similar
variations can be seen in endemic areas where reported HEV
prevalence may range between 30% and 80% [78]. It is well estab-
lished that the HEV seroprevalence increases with age [20,22,79]
but an overall decline of anti-HEV has been observed during the
last two decades as e.g. recently shown for Germany. Here the
authors screened 1092 sera and found a prevalence of 51% in
1996, which dropped to 34% in 2011 [22].vol. 61 j 1418–1429
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Fig. 2. Clinical signs and serological markers during HEV infection over time.
(A) acute and (B) chronic HEV infection.
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Clinical course of HEV infection
Clinical symptoms occur in only 2–5% of patients with acute HEV
infection as suggested by data from a large, double-blinded pla-
cebo controlled vaccine trial from China where more than
110,000 individuals have been followed [80]. From apparent
cases, mortality rates were estimated to be between 0.5–3%
[81], leading up to 70,000 deaths worldwide each year [82].
Importantly, risk factors have been identiﬁed, which are associ-
ated with a more severe outcome of infection. In particular, preg-
nant women seem to be at risk where infection with HEV
genotype 1 has been linked with foetal and maternal mortality
in up to 25% of cases [3]. Distinct polymorphisms in the proges-
terone receptor may explain in part the particular severe out-
come in pregnant women [79], but the detailed underlying
pathomechanism has not been fully understood thus far. Fulmin-
ant disease progression seems also to occur more often in
patients who already suffer from an underlying chronic liver dis-
ease [4–7]. Additionally, prolonged alcohol abuse serves as a risk
factor for fulminant acute hepatitis E [83]. The course of acute
HEV infection seems to differ between HEV genotypes as geno-
type 1 infection is associated with more severe cases than infec-
tion with genotype 3 HEV [84], however speciﬁc viral sequence
variations could not be linked to fulminant hepatitis E [85].
Acute hepatitis E in immunocompetent individuals
The clinical course of acute hepatitis E in immunocompetent
individuals is indistinguishable to infection with the hepatitis A
virus. After an incubation period of 2–8 weeks initial symptoms
are usually unspeciﬁc and include ﬂu-like symptoms like
myalgia, arthralgia, weakness, loss of appetite, abdominal pain
and vomiting [86]. Together with the elevation of liver enzymes,
in particular aminotransferases, alkaline phosphatase, c-glutamyl-
transferase or bilirubin, liver-speciﬁc symptoms like jaundice,
pruritus or decolouring of the stool can occur. These symptoms
usually resolve spontaneously within 4–6 weeks [87]. Only a
minority of infected individuals will develop fulminant hepatitis
with the need for initiation of antiviral therapy and/or liver trans-
plantation (Fig. 2A).
HEV infection in immunocompromised individuals
HEV infection may be associated with prolonged viraemia in
immunocompromised individuals as shown for various cohorts
of transplanted individuals [14]. Individuals may have impaired
cellular and humoral responses against HEV, explaining the lack
of control against HEV infection [14,88]. Similarly, HIV positive
patients with low CD4+ cell count are at risk for chronic hepatitis
E [15,16] as well as patients with other types of impaired cellular
immunity [17–19]. In general, a viral infection lasting for
6 months or longer is considered a chronic infection. However,
it has been suggested to classify HEV infection as chronic already
after 3 months of persistent infection as no spontaneous clear-
ance occurred thereafter in one study [89]. Overall, chronic
courses of HEV infections have been reported in up to 50–60%
of organ transplant recipients [90]. Chronic hepatitis E is fre-
quently associated with a mild elevation of liver enzymes usually
not exceeding 100–300 U/L and clinical signs of hepatitis are rare.
However, ﬁbrosis progression can be quite rapid within the ﬁrst
years of infection and several cases of fatal end-stage liverJournal of Hepatology 2014disease, possibly caused by chronic hepatitis E, have been
reported [90–92]. It is important to note that chronic HEV infec-
tion has thus far been observed almost exclusively in genotype 3
infected individuals (Fig. 1 and 2). However, a recent report from
China provided evidence, that genotype 4 HEV is also able to lead
to a chronic course of infection as shown for a boy who received
intensive chemotherapy due to an acute lymphoblastic leukae-
mia [93]. Interestingly, there was no evidence for chronic hepati-
tis E in a cohort of highly immunosuppressed kidney transplant
recipients in India where HEV genotype 1 is the predominant
genotype [94], indirectly suggesting that HEV genotype 1 may
not cause chronic hepatitis E.
Extrahepatic manifestations
There is increasing evidence that HEV infection may also cause
extrahepatic manifestations, supported by in vitro data which
delineated that HEV is able to replicate in non-liver cells such as
human intestine or monkey kidney cells [95]. In humans, HEV
infection has been linked with a reduction in kidney function
associated with persistent cryoglobulinemia [28]. Moreover, a
variety of neurological symptoms may be explained in part by
HEV infection [25–27]. A large case-control study from Rotterdam
involving 201 patients with Guillain–Barrè syndrome (GBS) sug-
gested that up to 5% of GBS patients had acute hepatitis E [27].
Whether these neurological symptoms are mediated by immuno-
logical features or are due to a direct infection of distinct brain
cells with HEV is unclear. Of note, HEV RNA has been found in
the spinal cord ﬂuid of patients suffering from neurological disor-
ders during HEV infection [96]. Interestingly, when the viral RNA
genome was sequenced Kamar et al. found a phylogenetic distinct
RNA arguing for an extrahepatic replication of the virus [97].vol. 61 j 1418–1429 1421
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Further manifestations, associated with HEV include cases
with acute pancreatitis, haematological abnormalities as well as
myopathies [98]. Of note, extrahepatic symptoms may also
develop even after HEV clearance as recently suggested for a liver
transplant recipient who developed vasculitis and enteritis after
HEV RNA became negative [99].Diagnosis of HEV infection in immunosuppressed patients
HEV infection can be diagnosed in immunocompetent individuals
by detection of anti-HEV IgM antibodies. Anti-HEV IgM titers
increase with the onset of clinical symptoms. However, the ana-
lytical sensitivity of the anti-HEV IgM assays can differ [100],
which potentially represents a major problem in patients receiv-
ing immunosuppressive medications. Indeed, delayed diagnosis
of HEV infection has been reported in a liver transplant recipient
due to variable performance of serologic assays [101]. Detection
of anti-HEV IgG indicates successful clearance of a previous infec-
tion and may be associated with some level of protection against
HEV re-infection even though HEV antibodies are not able to pro-
vide complete sterilizing immunity against HEV [102] (Fig. 2A).
Anti-HEV-IgG can also diminish over time [103] and thus, sero-
negativity may not exclude previous exposure to HEV. Overall,
testing for immunoglobulins has limitations in speciﬁcity and
sensitivity [75,76,104]. Reliability seems more accurate in
genotype 3 infection than in other genotypes. In addition,
cross-reactivity to other viruses has been observed [105,106].
Anti-HEV testing may frequently be false negative in immuno-
compromised individuals. Time to seroconversion – meaning
development of anti-HEV IgG – is delayed in patients after liver
transplantation and some patients may never develop detectable
anti-HEV IgG antibodies during chronic infection [92].
Considering the limitations of the antibody assays, diagnosis
of HEV infection should be based on detection of HEV-RNA in
organ transplant recipients. Still, even HEV PCR assays are not
perfect as sensitivities may show substantial variability and most
previous studies have been performed with in-house assays
[107]. Moreover, not all published assays have been optimized
for different HEV genotypes and a recent comparative study
showed that up to one out of six HEV RNA positive samples were
incorrectly classiﬁed as HEV RNA negative [108]. Importantly, the
WHO established an internal control for RNA ampliﬁcation tech-
nology in 2011, which should help to solve some of the technical
issues [107].
An alternative to HEV RNA assays could be HEV antigen test-
ing. HEV antigens may show different kinetics than HEV RNA and
have been shown to be longer positive than HEV RNA in patients
with acute hepatitis E [109]. A commercial sandwich ELISA for
the detection of the HEV-capsid is available. However, this test
seems to be less sensitive than RNA-techniques and the role for
detection of infection needs to be evaluated in more detail in
future studies [110] (Fig. 2B).Prevalence and clinical course of hepatitis E in liver-
transplant recipients (summarized in Table 1)
The ﬁrst case series demonstrating chronic HEV infection in
transplanted individuals also included three liver transplant
recipients [13]. Overall, 14 solid-organ transplanted patients with1422 Journal of Hepatology 2014acute HEV infections were identiﬁed. Out of these, 8 patients
developed persistent infection, which interestingly included all
three liver transplanted individuals. The study demonstrated a
rather rapid histological disease progression within a median
time of follow-up of only 18 months. Subsequently, various
further studies have been published, addressing the role
chronic infection in organ transplant recipients including liver-
transplanted individuals. Overall, several cases of chronic hepati-
tis E after liver transplantation were identiﬁed even though the
absolute frequency was low with 1–3% in most studies. Consider-
able differences between countries were evident.
In 2009, a study from the Netherlands was published [111],
screening 285 patients, which had undergone liver transplanta-
tion, for HEV-RNA, anti-HEV IgM and IgG levels. 96% of these indi-
viduals were HEV RNA and anti-HEV IgG/IgM negative and thus,
had no evidence for post-transplant HEV infection. One female
patient was identiﬁed with ongoing chronic hepatitis caused by
HEV – without displaying any HEV-speciﬁc antibody-titres. She
subsequently had to be re-transplanted due to liver cirrhosis.
However, the new graft became re-infected and persistent HEV
infection sustained in the absence of anti-HEV antibodies. Over-
all, 9 patients were IgG positive after transplantation (3.1%). Ret-
rospective analysis of stored samples revealed the presence of
anti-HEV already before transplantation in 6 of these 9 individu-
als. Two patients seroconverted to anti–HEV IgG positive after
transplantation. One of the patients developed anti-HEV IgG dur-
ing a chronic phase of infection, which started 18 month after
transplantation and lasted until 60 month post-transplantation.
This patient then cleared the infection spontaneously. Whether
a change in immunosuppressive medication was associated with
HEV clearance was not reported in the publication.
The ﬁndings were later conﬁrmed by another study from The
Netherlands [112]. The authors retrospectively screened a large
cohort of solid-organ recipients (total N = 1200, liver: n = 300)
for HEV-RNA. In total, 12 patients were HEV-RNA positive of
which 4 had undergone liver transplantation. One of these
cleared the virus within a few days, all others – and in particular
all of the liver transplanted – became chronically infected. Impor-
tantly, the authors also delineated that the time of initial HEV-
infection and the ﬁrst detection of anti-HEV-IgG spanned on
average 32–124 days, supporting the need for evaluation of
HEV-RNA when HEV infection is suspected in immunocompro-
mised individuals.
The experience from the Netherlands was largely in line with
observations from northern Germany, which were published in
2010 [92]. A retrospective screening of liver transplanted individ-
uals tested 226 patients who all had elevated liver enzymes. HEV
infection was identiﬁed as a probable cause of hepatitis in three
individuals with two patients becoming chronically infected. One
of the persistently infected patients developed rapid progression
of liver ﬁbrosis within 2 years. The prevalence of anti-HEV was
higher in the liver transplanted group (4.4%) compared to 3% in
non-transplanted individuals with chronic liver diseases and 1%
in healthy controls.
Several studies from France investigated the prevalence of
hepatitis E in immunosuppressed patients. Markers of HEV infec-
tion were studied in a cohort of liver transplanted individuals
who received transplantation between 2005 and 2012 in the
Rhône-Alpes-region [113]. HEV seroconversion was observed in
7.7% of patients after a median follow-up of 33 months. The
authors estimated the HEV incidence rate to be 2.83 cases pervol. 61 j 1418–1429
Table 1. Overview and hallmark studies investigating HEV infection in cohorts of liver transplanted individuals.
Author,
[Ref.]
Year Country/
area
Cohort Seroprevalence/incidence Hallmark of the study
Kamar et al.,
New England Journal 
of Medicine [13]
2008 France 217 solid organ 
transplantation 
patients with elevated 
liver enzymes (liver: 
n = 86) (adult), 
retrospectively
prevalence 10% 14 solid organ transplanted individuals (3x 
liver, 9x kidney, 2x kidney and pancreas) had 
acute HEV infection, all liver donors developed 
chronic HEV infection; Metavir fibrosis score (in 
liver transplanted individuals) was assessed in 
two patients, one progressed in fibrosis (F1 to
F2, Metavir activity score 0 to 3) in 15 month of 
follow-up, the other one did not show progression 
in 17 month
Haagsma et al.,
Liver Transplantation 
[111]
2009 The 
Netherlands
285 liver transplanted 
patients (adult), 
retrospectively
prevalence 3% One chronically infected individual cleared the 
virus spontaneously, 1 patient had to undergo 
re-transplantation due to chronic infection
Buti et al.,
Liver Transplantation 
[115]
2009 Spain 108 solid organ 
recipient (kidney: 
n = 21, liver: n = 82, 
combined n = 5)
(adult), retrospectively
prevalence overall 2.7%, in liver 
transplanted 3.7%
No patient with ongoing HEV-infection (drawback: 
only IgG-positive individuals were tested for IgM 
and HEV-RNA)
Halac et al.,
Gut [116]
2010 Canada 80 liver transplanted 
individuals (children), 
retrospectively
prevalence 13-23% 2/3 of the patients which had signs of hepatitis 
post-transplant acquired anti-IgG-positivity over 
time. One individual had chronic infection and 
displayed cirrhosis of the graft
Pischke et al.,
Liver Transplantation 
[92]
2010 Germany 226 liver transplanted 
individuals (adult), 
retrospectively
prevalence 4.4% 3 acutely HEV-infected patients, two became 
chronically infected; prevalence in liver-
transplanted individuals 4.4% (n = 226), in non-
transplanted individuals with liver disease 3% 
(n = 129) and 1% in healthy control (n = 108)
Legrand-Abravanel 
et al.,
Emerging Infectious 
Diseases [114]
2011 France 871 solid organ 
transplanted patients 
(kidney: n = 700, 
liver: n = 171) (adult), 
retrospectively
prevalence overall 14%, liver 
transplanted 12%; incidence 
overall 3.2 per 100 person-
years, for liver 4.8 cases per 100 
person-years
6 liver transplanted patients became 
chronically infected; low age (under 52) and 
liver transplantation served as risk factors for 
acquiring HEV-infection
Kamar et al.,
Gastroenterology [90]
2011 Multicenter 
study, 
Europe and 
US
85 solid organ 
transplanted patients 
with acute HEV-
infection (liver: 
n = 24) (adult), 
restrospectively
no prevalence tested Reduction of immunosuppression leads 
to clearance in 30% of the cases; liver 
transplantation as well as use of tacrolimus are 
risk factors for chronic infection, 66% of acutely 
infected, transplanted patients developed chronic 
infection; 14.3% of chronically infected patients 
developed liver cirrhosis. Two liver transplant 
patients required a second liver transplant due to 
HEV-related cirrhosis
Pas et al.,
Emerging Infectious 
Diseases [112]
2012 The 
Netherlands
1200 solid organ 
recipients (heart:
n = 259, lung: n = 53, 
liver: n = 300, kidney: 
n = 574, multiple: 
n = 14) (adult), 
retrospectively
no prevalence tested 12 patients were positive for HEV-RNA (liver: 
n = 4); 11 had chronic infection (liver: n = 4)
Buffaz et al.,
European Journal of 
Clinical Microbiology 
& Infectious Diseases 
[113]
2014 France 206 liver transplanted 
individuals (adult 
and pediatric), 
retrospectively
prevalence 28%; incidence 2.83 
cases per 100 person-years
3 chronically infected patients; 2 of these 
displayed anti-HEV IgG titers pre-transplantation 
which did not lead to protection of infection 
post-transplantation; seroconversion after liver 
transplantation was observed in 11 individuals 
during follow-up (mean 33 month)
Sherman et al.,
Journal of Viral 
Hepatitis [139]
2014 USA 590 HIV-positive 
transplanted 
individuals (liver: 
n = 273)(adults), 
retrospectively
prevalence 18.9% in liver 
recipients
0.9-1.8% of liver transplanted individuals were 
anti-HEV IgM positive and none of the kidney 
transplant recipients; one patient with borderline 
anti-HEV IgM had cirrhosis; no patient was 
detected HEV-RNA positive
Galante et al.,
ILTS, London [140]
2014 Germany 287 liver transplant 
recipients (adults), 
prospectively
no prevalence tested 4 patients had chronic HEV-infection
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100 person-years. Only one of the seroconverted patients was
also HEV RNA positive. In addition, the authors identiﬁed 2
patients with chronic hepatitis E who had already been anti-
HEV IgG seropositive prior to transplantation. Based on this
observation the authors concluded that HEV clearance before
transplantation and presence of HEV antibodies may not protect
from HEV infection in the context of immunosuppression after
liver transplantation. However, one drawback of the study was
that HEV-RNA-testing was performed only in individuals who
were anti-HEV-IgM and IgG positive. Therefore, anti-HEV anti-
body-negative/HEV-RNA-positive patients would not have been
detected with this screening approach.
In another study from Toulouse (France) a large number of
kidney- (n = 529) and liver-transplanted (n = 171) individuals –
transplanted between 2004 and 2008 – were retrospectively
assessed for signs of HEV infection [114]. HEV infection after
transplantation occurred in 34 patients (kidney recipients
n = 22, liver n = 12). 14 patients seroconverted post-transplanta-
tion, while HEV-RNA remained negative. However, 20 patients
who did not develop antibodies against HEV had detectable HEV
RNA. The HEV incidence rates were calculated with 2.7 per 100
person-years in kidney recipients and 4.8 per 100 person-years
in liver recipients. A chronic course of HEV infection was observed
in 16 patients (47%). Strikingly, age under 52 at time of transplan-
tation as well as receiving a liver transplantation were risk factors
for acquiring HEV infection in the multivariate analysis.
There are also data from Spain. In 2010, Buti et al. investigated
the HEV-prevalence in solid-organ-transplanted individuals by
testing anti-HEV IgG when an elevation of liver enzymes was
observed (kidney: n = 21, liver: n = 82, combined n = 5) [115].
Patients positive for IgG were also tested for anti-HEV-IgM as
well as for HEV-RNA. Overall, only three liver transplanted
patients were anti-HEV IgG positive. There was no evidence for
persistent infections. Also in this study it has to be considered
that HEV-RNA testing was performed only in anti-HEV IgG posi-
tive samples and thus the true prevalence of HEV infection could
have been underestimated.
Factors potentially associated with chronic HEV infection in
solid organ transplant recipients were investigated in a large
multi-centre study involving 17 transplant centres throughout
Europe and the US [90]. Overall 83 patients were enrolled includ-
ing 26 liver transplant recipients. Interestingly, in this cohort the
majority of liver-transplanted individuals developed chronic
infection (22 of 26 infected individuals) which was signiﬁcantly
more frequent than in non-liver transplanted patients (34 of
59) supporting the hypothesis that the risk for persistent infec-
tions is higher after liver transplantation.
Sherman et al. studied HIV-infected kidney and liver trans-
planted individuals in the US for markers of HEV-infection. In
590 individuals (including 273 patients after liver transplanta-
tion) the authors found an anti-HEV IgG prevalence of 20% in
both, liver and kidney transplanted patients. However, testing
for HEV-RNA revealed no ongoing infection in any case.
The prevalence of HEV infection in children after liver
transplantation was investigated in a Canadian study [116]. The
authors screened 80 children transplanted between 1992 and
2010. Liver enzymes were normal in 66 children while 14 had
persistently elevated ALT levels. Individuals with normal liver
enzymes tested anti-HEV IgG positive in 15% of cases while
two-thirds of the children with elevated liver enzymes
seroconverted after liver transplantation. Additionally, seven of1424 Journal of Hepatology 2014the children with elevated liver enzymes had detectable
anti-HEV IgM more than once during follow-up and these
patients also had histological signs of inﬂammation and ﬁbrosis
progression. One girl tested repeatedly HEV-RNA positive and
unfortunately developed liver cirrhosis further highlighting the
progressive nature of persistent HEV infection in immunosup-
pressed patients.Role of immunosuppression in solid-organ transplanted
individuals and HEV
Immunosuppressive drugs may interfere with replication of dif-
ferent viruses. It has, for example, been shown for HCV that ste-
roids may increase HCV infectivity by upregulation of distinct
entry receptors [117] and that cyclosporine can inhibit viral rep-
lication by interfering with cyclophilins [118]. There is also some
evidence that the immunosuppressive regime may be important
for HEV infection. Initial data suggested that chronic cases of hep-
atitis E aremore likely in liver- and kidney transplanted patients if
patients were treated with the calcineurin-inhibitor tacrolimus as
compared to patients receiving cyclosporine [90]. In contrast,
heart transplant recipients receiving mycophenolate did not
develop persistent infection [91]. Of note, these clinical data have
meanwhile been supported by studies investigating the effects of
different drugs on HEV infection in vitro. The studieswere possible
due to the development of a robust in vitro model for HEV geno-
type 3 infection [119]. Interestingly, addition of tacrolimus
increased viral replication supporting the clinical observations
[120]. However, the other calcineurin inhibitor cyclosporine A
also increased replication, which could not be conﬁrmed yet in
patient cohorts. Different mTOR-inhibitors, rapamycin and ever-
olimus also led to an enhanced replication of HEV transfected cells
in vitro, involving phosphorylated 4E-BP1 in infected hepatocytes
[121]. However, the clinical impact of this ﬁnding is unclear at this
stage. The use of corticosteroids does not seem to impact replica-
tion of HEV, both in vivo as well as in vitro. Strikingly, the use of
mycophenolate-mofetil leads to a signiﬁcant decrease of viral rep-
lication in vitro, which would on the ﬁrst view support the above
mentioned clinical observation in heart transplant recipients
[91,120]. The mechanism is likely to be linked to IMPDH inhibi-
tion by mycophenolate [122]. However, mycophenolate-mofetil
might also negatively inﬂuence leucocyte cell count and subse-
quently promote chronicity of infection [14,88]. Thus, it is unclear
to what extent the beneﬁcial in vitro effects of mycophenolate
really translate into clinical beneﬁts. Indeed, many patients with
chronic hepatitis E in the literature received mycophenolate as
part of their immunosuppressive regimen.
Overall, the choice of the immunosuppressive drugs seems to
be of important for liver transplant recipients with hepatitis E.
Still, both experimental and clinical data are very limited. At
present one could suggest that tacrolimus and mTOR inhibitors
should be avoided once chronic infection is evident, while ste-
roids, cyclosporine and mycophenolate might be preferred com-
pounds. However, there is not sufﬁcient evidence yet to
propose distinct ‘‘pre-emptive’’ immunosuppressive regimens to
avoid chronic infections after exposure or to propose speciﬁc
drug changes once persistent HEV infection has developed.
Rather than discussing one drug vs. another it seems to be more
important to reduce the overall level of immunosuppression as
much as possible in patients with chronic hepatitis E.vol. 61 j 1418–1429
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HEV reactivation
In 2009 le Coutre et al. reported the case of a patient with acute
lymphatic leukaemia who displayed an acute, self-limiting HEV
infection prior to allogenic stem cell transplantation [123].
14 weeks after transplantation reappearance of HEV viraemia
was observed. Sequencing analysis conﬁrmed the presence of
identical viral strains prior to transplantation and at the time or
reactivation suggesting prolonged viral persistence in the
absence of detectable viraemia. For kidney-transplanted individ-
uals no HEV reactivation has yet been described [124] while HEV
can be transmitted by liver transplantation as for example delin-
eated by Haagsma et al. [125] and Schlosser et al. [73].Prevention of HEV infection
HEV, being a non-enveloped virus, is relatively robust and stable
upon environmental harms. The risk of food-borne HEV can be
signiﬁcantly reduced by cooking of meat. In vitro assays suggest,
that cooking meat for 1 min at 70 C is efﬁcient in reducing viral
infectivity [126,127]. In theory, transmission by contact with
raw meet seems possible, although not described in the litera-
ture so far. Therefore, this risk should be reduced by washing
hands after exposure to potentially infected meat. Blood prod-
ucts are not routinely tested until now and it is unclear whether
common inactivation procedures cause elimination of infectious
HEV-particles. Although, direct human-to-human transmission
of HEV is usually uncommon, patients should be advised to per-
form regular cleaning of shared sanitary facilities. If one pre-
sumes similar stabilities of HEV and HAV, HAV is partially
resistant to 80% ethanol-based disinfectants, which should not
be recommended alone for the decontamination of HEV either
[128]. Overall, intra-family or direct person-to person transmis-
sion seems to be a seldom event but have been described and
suggested in a few cases [129]. Therefore, testing of partners/
family-members should be considered if risk factors for the
development of severe infection are present including organ
transplantation.
A vaccine against HEV was licensed in China which showed an
efﬁcacy of 94%-100% in a large-scale vaccine trial involving more
than 100,000 individuals [80]. Unfortunately, this vaccine has not
been approved yet in other countries and the efﬁcacy to protect
from HEV genotype 3 infections has also not formally been pro-
ven – even though the genotype 1- based vaccine was effective
against HEV genotype 4 infections in China. A vaccine against
HEV would be highly desirable, especially for patients at risk to
develop fulminant acute HEV infection or to become chronically
infected. However, even if a vaccine would be available it is
unclear if the approach would be effective in immunosuppressed
patients as antibody-titres might not be sufﬁcient to protect
against infection. This is supported by the study from Buffaz
et al. who observed chronic HEV infections even in patients
who displayed anti-HEV IgG before transplantation [113]. In line
with this, Abravanel et al. recently also reported infection of
solid-organ transplanted individuals, which were anti-HEV IgG
positive prior to liver transplantation. They propose that an
HEV antibody-titre below 7 WHO units/ml is not sufﬁcient to
protect from HEV-infection in this cohort. Additionally, they
delineated that these infections can lead to both, acute and
chronic HEV infection [130].Journal of Hepatology 2014Treatment
HEV-infection is usually subclinical in immunocompetent indi-
viduals and does therefore not require speciﬁc therapies in the
vast majority of cases. However, antiviral treatment of severe
acute infections should be considered in patients with risk factors
for fulminant liver failure. Ribavirin seems to be the treatment of
choice as it can lead to a rapid decrease of viral load in patients
with acute severe hepatitis E [131–133]. Of note, ribavirin was
also beneﬁcial not only in genotype 3 infection but also in one
patient with very severe acute HEV genotype 1 infection [84].
Based on this – still rather limited – data, we would recommend
to treat acute hepatitis E patients at risk of developing liver fail-
ure with ribavirin not only to prevent organ failure but also to
avoid HEV transmission if liver transplantation is still needed.
However, the speciﬁc role of ribavirin as pre-emptive therapy
to avoid infection of the transplanted graft requires further
investigation.
Chronic hepatitis E should be avoided in liver transplant recip-
ients to prevent ﬁbrosis progression. The ﬁrst steps in the man-
agement of a transplanted patient with persistent HEV infection
would be the re-evaluation of immunosuppressive drugs based
on effects on HEV replication as discussed above and – if possible
– to reduce the intensity of immunosuppression, which may lead
to HEV RNA clearance in approximately 30% of cases [90]. If HEV
is not cleared, antiviral therapies should be considered.
Two case reports describing in total 5 liver transplanted indi-
viduals showed that chronic hepatitis E may be treated with PEG-
interferon alpha [134,135]. HEV RNA became negative over a
treatment course of 3–12 months. However, interferon alpha
treatment is associated with side effects and may also induce
graft rejection. Thus, only well selected patients with chronic
hepatitis E may be candidates of PEG-IFNa therapy.
First case series, reporting an antiviral efﬁcacy of ribavirin
monotherapy have been reported by two French centres in 2
and 6 individuals with persistent HEV infection, respectively
[136,137]. Patients were treated for 3 months with a ribavirin
dose of 600–800 mg per day and six of the eight patients experi-
enced a virological response with sustained clearance of HEV,
while two patients relapsed after the end of therapy. These ﬁnd-
ings were then reproduced by different centres. In Hannover
(Germany), patients were treated for a longer time (5 months)
and 9/11 patients achieved HEV RNA clearance. However and
importantly, one patient showed a virological breakthrough
when the ribavirin dose was reduced due to anaemia. Clinical
resistance was evident as no further viral decline was observed
even when the ribavirin dosing was increased again [84]. The
so far largest cohort of ribavirin-treated patients was reported
recently from France describing a retrospective analysis of 59
solid-organ transplanted patients with chronic hepatitis E
[138]. Patients received ribavirin at a dose of 8 mg per kg body
weight for a median of 3 months (range 1–18 months). A sus-
tained virological response could be reached in 46 of the 59
patients. Interestingly, all patients who failed to clear HEV during
the initial course of ribavirin therapy showed a sustained virolog-
ical response when re-treated with ribavirin for a longer period.
Overall, clearance of HEV was observed in 95% of the cases (2
patient still received retreatment, 2 patients died of HEV- and
treatment-unrelated reasons, 2 patients declined to undergo re-
therapy and 2 were lost during follow-up). In the multivariate
analysis a low lymphocyte count was predictive for non-responsevol. 61 j 1418–1429 1425
Table 2. Overview and hallmark reports investigating different treatment options of chronic HEV infection in liver transplanted individuals.
Author, [Ref.] Treated individuals Antiviral drug/intervention Outcome/Hallmarks
Kamar et al., 2010;
Clinical Infectious 
Disease [92]
3 liver transplanted PegIFNα-2a 2 patients cleared infection, 1 individual relapsed
Haagsma et al., 2010;
Liver Transplantation 
[135]
2 liver transplanted PegIFNα-2a One patient cleared under treatment; the other patient was treated for 16 
weeks, but still displayed detectable HEV-RNA. This person resolved 4 weeks 
after discontinuation, during which period levels of tacrolimus were rather low
Pischke et al., 2013;
Liver International [84]
5 kidney-, 4 heart-, 
4 lung-, 2 liver 
transplanted
Ribavirin or reduction of 
immunosuppression
Overall, reduction of immunosuppression led to HEV-clearance in three 
patients. 11 patients recieved ribavirin, 9 of these cleared the virus, one 
patient died due to treatment- and HEV-unrelated disease, one patient 
remained HEV-RNA positive and died later due to liver related disorders. Both 
liver transplanted individuals resolved by reduction of immunosuppression
Junge et al., 2013;
Pediatric 
Transplantation [141]
1 liver transplanted Ribavirin The patient cleared infection under treatment
Kamar et al., 2014;
New England Journal of 
Medicine [138]
37 kidney-, 5 heart-, 
5 kidney & pancreas-, 
2 lung-, 10 liver 
transplanted
Ribavirin Overall, HEV clearance under therapy was achieved in 95% of the patients, 
recurrence of HEV-RNA was detected in 10 patients after the end of 
treatment, 7 of these patients underwent re-treatment which led to sustained 
virological response in 4 individuals, 2 were HEV-RNA negative and still 
recieved therapy and 1 patient was HEV-RNA negative 3 month after the end 
of re-treatment; in liver transplanted individuals 8 had sustained virological 
response, while 2 had no sustained virological response after initial treatment; 
associated with a sustained virologic response; a positive test for HEV RNA 
at month 1 of treatment increased the likelihood for failure to achieve a 
sustained virological response
Klein et al., 2014;
Experimental and 
Clinical Transplantation 
[142]
1 liver transplanted Ribavirin The patient cleared infection under treatment
Galante et al., 2014;
oral presentation ILTS 
London[140]
4 liver transplanted Ribavirin 3 patients resolved, 1 patient relapsed after therapy and is still receiving 
retreatment
a higher lymphocyte count at the initiation of ribavirin was significantly
Frontiers in Liver Transplantationto treatment. Of note, anaemia was a dominant side effect requir-
ing reduction of ribavirin in 29% of the patients. This underlines
that patients with poor performance status and comorbidities
may not be applicable for ribavirin treatment and that alternative
antiviral treatment are still needed.
Studies, investigating antiviral regimes speciﬁcally in liver
transplanted individuals are not yet available. However, available
data prompt for ribavirin being the treatment of choice (Table 2).Concluding remarks
It is now well established that HEV infections can take chronic
courses in immunocompromised individuals and that the risk
for chronicity – even though based on limited data – may be even
higher for patients after liver transplantation. However, the over-
all frequency of HEV infection in European and North American
transplant cohorts is low. HEV RNA testing of patients with ele-
vated liver enzymes only seems to be a reasonable approach.
HEV genotype 3 infection is a zoonosis and liver transplant recip-
ients have to be advised to avoid the consumption of raw and
uncooked meat. Transfusion of HEV by blood has to be considered
and HEV RNA testing of blood products is currently under debate
in several countries. Chronic hepatitis E is often associated with a
particular rapid progression to liver cirrhosis and should there-
fore not be missed. The choice of immunosuppressive drugs is
important in case of HEV infections as distinct effects on HEV rep-
lication (either inhibitory or stimulatory) have been described.1426 Journal of Hepatology 2014An antiviral treatment option is available with ribavirin, which
should be given for at least 3 months, however, treatment failures
may occur supporting ongoing research to identify additional
treatment options for a frequent and largely underestimated
infectious complication after liver transplantation.Conﬂict of interest
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